INVERNESS MEDICAL INNOVATIONS, INC., as Issuer, the GUARANTORS named herein, as Guarantors, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of August 11, 2009 7.875% Senior Notes due 2016Supplemental Indenture • August 11th, 2009 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of August 11, 2009 (this “Supplemental Indenture”), among Inverness Medical Innovations, Inc., a Delaware corporation, as Issuer (the “Issuer”), each of the Guarantors named herein, as Guarantors, and The Bank of New York Mellon Trust Company, N.A., a national banking association, as Trustee (the “Trustee”).
INVERNESS MEDICAL INNOVATIONS, INC., as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of August 11, 2009Inverness Medical Innovations Inc • August 11th, 2009 • In vitro & in vivo diagnostic substances • New York
INDENTURE dated as of August 11, 2009 between Inverness Medical Innovations, Inc., a Delaware corporation, as Issuer (the “Issuer”), and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”).
Inverness Medical Innovations, Inc. $150,000,000 7.875% Senior Notes due 2016 UNDERWRITING AGREEMENTUnderwriting Agreement • August 11th, 2009 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
JEFFERIES & COMPANY, INC. GOLDMAN, SACHS & CO. WELLS FARGO SECURITIES, LLC As Representatives of the several Underwriters c/o 520 Madison Avenue New York, New York, 10022
